Lower-extremity amputation (LEA) is one of the complications of diabetes that is perhaps most feared by patients with this disease ([@B1]) and rightfully so. These LEAs are generally the end point of a characteristic sequence of events: a foot wound, usually a consequence of peripheral neuropathy, becomes infected and does not respond to treatment ([@B2]). More than 60% of nontraumatic LEAs in the U.S. occur among people with diabetes, in whom the rate is 6 to 10 times higher than for people without diabetes ([@B3]). After a first LEA, up to 50% of patients require another amputation within 3--5 years. Furthermore, the 5-year mortality after LEA is \~50% ([@B4]), with the risk considerably higher for diabetic compared with nondiabetic patients ([@B5]).

Considering the substantial morbidity and mortality associated with LEA in people with diabetes, the ability to identify which patients hospitalized for a diabetic foot infection are at highest risk for this complication could help clinicians direct special prevention efforts to these individuals. This information also could help identify the baseline risk for LEA among patients admitted to a medical center, allowing fairer comparisons of amputation rates at different centers. Although the factors associated with diabetic people developing a foot ulcer are well defined ([@B1]), risk factors for amputation are less clear. Previous studies have identified independent risk factors that include (in approximate order of odds ratio) a history of a foot ulcer ([@B6]), limb ischemia, underlying bone involvement, the presence of gangrene (e.g., a higher Wagner grade), deep wounds, older age, elevated inflammatory markers ([@B7]), poor glycemic control ([@B8]), a specific ethnicity or geographical region ([@B9],[@B10]), nephropathy ([@B8]), and retinopathy ([@B6]). To determine whether we could develop and validate a scoring system to predict the risk of LEA, we examined data from a large group of patients hospitalized with a diabetic foot infection.

RESEARCH DESIGN AND METHODS {#s5}
===========================

We used data from a clinical research database of patients hospitalized at 97 acute-care hospitals in the U.S. that was compiled by CareFusion (Department of Clinical Research, CareFusion, Marlborough, MA). The database includes extensive data in the following categories: clinical (including diagnoses and vital signs); laboratory (e.g., chemistry, hematology, and microbiology); and administrative (e.g., demographics, admission source, length of hospitalization, and discharge status). Eligible patients were those discharged from one of the designated hospitals between 1 January 2003 and 30 June 2007 with a principal diagnosis (ICD-9-CM) of diabetes and a secondary diagnosis indicating skin or soft-tissue infection (including cellulitis, infected ulcer, or surgical-site infection \[SSI\]) that was culture documented within 48 h of admission. This study was approved by the New England Institutional Review Board Human Subjects Research Committee (Wellesley, MA) and was conducted in compliance with the Health Insurance Portability and Accountability Act.

Study design and statistical analysis {#s6}
-------------------------------------

We randomly split the study population into two groups: one for model derivation (75% of the population) and the other for model validation (the remaining 25%). Candidate predictor variables used in the model were demographic data, a history of previous health care--associated infection, clinical presentation, concomitant chronic disease(s), previous LEA, and type of skin or soft-tissue infection (cellulitis, ulcer or other infection, or SSI). Our outcome measure of interest was LEA during the index hospitalization, which was identified by ICD-9 procedure codes (841.1 amputation, toe; 841.2 amputation, foot; 841.3 disarticulation, ankle; 841.4 amputation, Malleoli; 841.5 amputation, knee, below NEC \[not elsewhere classified\]; 841.6 disarticulation, knee; and 841.7 amputation, knee, above).

Using the derivation cohort, we conducted univariate analyses to determine the proportion of patients with each candidate predictor who underwent an LEA. We then fit a stepwise multivariate logistic regression model to identify independent predictors of LEA and to estimate their relative predictive weights (coefficients). Using previously published methods, we converted the coefficients for the independent predictors into a simplified risk score system ([@B11]). Specifically, we calculated the number of points assigned to each variable by dividing its regression coefficient by the smallest coefficient in the model then rounded this quotient to the nearest whole number. We then calculated each subject's LEA risk score by summing up the points of all variables present on admission. We then validated the risk score system using the remaining 25% of the population.

We assessed model discrimination using the c-statistic, which defines how well a model or prediction rule can discriminate between patients who do and do not have an event and measures how well a clinical prediction rule correctly ranks patients in order by risk. We assessed model calibration using the Hosmer-Lemeshow goodness-of-fit test, which assesses whether the observed and expected event rates match in subgroups of the model population. The test specifically identifies subgroups as the deciles of fitted risk values, and models with similar expected and observed event rates (i.e., a large *P* value) are considered to be well calibrated. We then used the Cochran-Armitage trending statistic, which modifies the χ^2^ test to incorporate a suspected ordering, to assess the ability of the risk score system to differentiate low-risk from high-risk patients in a graded response. All analyses were conducted using Statistical Analysis System (version 9.01; SAS Institute, Cary, NC).

RESULTS {#s7}
=======

Patient characteristics {#s8}
-----------------------

Among hospitalized patients, 3,018 met our inclusion criteria for a diabetic foot infection, with cellulitis (in 80%) and an infected ulcer (16%) being the most common diagnoses. We used 2,230 patients for the derivation cohort and 788 for the validation cohort; all baseline characteristics were similar between the two cohorts ([Table 1](#T1){ref-type="table"}). A total of 646 (21.4%) patients underwent an LEA during their index hospitalization; the number (and rate) in the derivation cohort was 463 (20.8%) compared with 183 (23.2%) for the validation cohort. For those patients undergoing an LEA, the median time from admission to amputation was 4 days, with an interquartile range of 2--7 days. A previous LEA of some type was noted in \~27% of patients in the derivation cohort and 26% in the validation cohort.

###### 

Characteristics for patients in the derivation and the validation cohorts

  Variable                                                                            Derivation cohort   Validation cohort
  ----------------------------------------------------------------------------------- ------------------- -------------------
  *n*                                                                                 2,230               788
  Mortality (death during hospitalization)                                            30 (1.3)            10 (1.3)
  Amputation during index hospitalization                                             463 (20.8)          184 (23.3)
  Median age (years \[first through third quartiles\])                                60 (50--71)         60 (50--71)
  Male sex                                                                            1,359 (60.9)        493 (62.6)
  Previous admission within ≤30 days                                                  214 (9.6)           68 (8.6)
  Transferred from an acute-care hospital                                             19 (0.9)            8 (1.0)
  Transferred from a skilled nursing facility                                         72 (3.2)            32 (4.1)
  Race/ethnicity                                                                                          
   White                                                                              1,574 (70.6)        593 (75.3)
   Black                                                                              420 (18.8)          115 (14.6)
   Other                                                                              236 (10.6)          80 (10.2)
  Comorbidities                                                                                           
   Congestive heart failure                                                           522 (23.4)          171 (21.7)
   History of coronary disease                                                        532 (23.9)          193 (24.5)
   Immunosuppressive medication                                                       73 (3.3)            33 (4.2)
   Cancer                                                                             46 (2.1)            12 (1.5)
   Peripheral vascular disease                                                        807 (36.2)          287 (36.4)
   Chronic liver disease                                                              31 (1.4)            9 (1.1)
   Chronic lung disease                                                               232 (10.4)          97 (12.3)
   Previous stroke                                                                    234 (10.5)          74 (9.4)
   Chronic renal disease                                                              445 (20.0)          153 (19.4)
   History of amputation                                                              611 (27.4)          203 (25.8)
   Renal dialysis treatment                                                           53 (2.4)            23 (2.9)
  Type of skin and soft-tissue infection                                                                  
   Cellulitis                                                                         1,788 (80.2)        629 (79.8)
   Infected ulcer                                                                     360 (16.1)          129 (16.4)
   Surgical site                                                                      82 (3.7)            30 (3.8)
  Severe infection clinical presentation                                                                  
   Systolic blood pressure \<100 mmHg                                                 293 (13.1)          110 (14.0)
   Temperature \<96°F or \>100.5°F                                                    681 (30.5)          238 (30.2)
   Pulse \<49 or \>125 bpm                                                            128 (5.7)           40 (5.1)
   Respiration \<10 or \>29 breaths per minute                                        86 (3.9)            35 (4.4)
   Altered mental status                                                              173 (7.8)           66 (8.4)
  Laboratory results                                                                                      
   Albumin \<2.8 g/dL                                                                 237 (10.6)          95 (12.1)
   Blood urea nitrogen \>40 mg/dL                                                     399 (17.9)          121 (15.4)
   Creatinine \>3 mg/dL                                                               176 (7.9)           65 (8.2)
   Sodium \>145 mEq/dL                                                                24 (1.1)            11 (1.4)
   Total bilirubin \>0.8 mg/dL                                                        206 (9.2)           89 (11.3)
   pO~2~ \<55 or \>140 or O~2~ sat \<90%                                              37 (1.7)            10 (1.3)
   Prothrombin time international normalized ratio \>1.2 or prothrombin time \>14 s   209 (9.4)           68 (8.6)
   Bands on leukocyte differential \>13%                                              80 (3.6)            29 (3.7)
   White blood cell count \>11,000 per mm^3^                                          1,037 (46.5)        397 (50.4)
  Glucose on admission (mg/dL)                                                                            
   ≤70                                                                                100 (4.5)           35 (4.4)
   71--135                                                                            331 (14.8)          124 (15.7)
   136--240                                                                           717 (32.2)          236 (29.9)
   \>240                                                                              1,082 (48.5)        393 (49.9)

Data are *n* (%), unless otherwise indicated. The *P* values for each variable is \>0.05, indicating that the derivation and validation cohorts are similar.

For the entire study cohort, the patients who underwent an LEA were significantly older (median age in years \[interquartile range\] 62 \[53--72\] vs. 60 \[50--71\]; *P* \< 0.0001), and their in-hospital mortality rate was significantly higher (2.3 vs. 1.1%; *P* \< 0.05) compared with patients who did not require amputation. The most common finding on culture was a polymicrobial (two or more different microorganisms) infection, which accounted for \~57% of all patients. A detailed accounting of pathogen distribution is shown in [Supplementary Appendix A](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0331/-/DC1).

Univariate analysis of risk factors associated with LEA {#s9}
-------------------------------------------------------

As shown in [Table 2](#T2){ref-type="table"}, in the derivation cohort the univariate analysis revealed that the following factors were significantly associated with LEA (*P* \< 0.05): older age; male sex; transfer from another hospital or nursing home; previous LEA; coronary, renal, or peripheral vascular disease; low serum albumin; elevated values for white blood cell count, prothrombin time or international normalized ratio, or creatinine; elevated body temperature; the presence of a foot ulcer; and the presence of an SSI.

###### 

Univariate analysis of risk factors associated with LEA in the derivation cohort

  Variable                                                                            Derivation cohort (% \[*n* LEA/*n* evaluable\]) (*n* = 2,230)   *P*[\*](#t2n1){ref-type="table-fn"}
  ----------------------------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------
  *n* cases                                                                           20.8 (463/2,230)                                                
  Mortality (death during hospitalization)                                            33.3 (10/30)                                                    0.1094
  Age ≥50 years                                                                       23.1 (394/1,708)                                                \<0.0001
  Male sex                                                                            22.3 (303/1,359)                                                0.0282
  Previous admission ≤30 days                                                         24.8 (53/214)                                                   0.1322
  Transferred from an acute-care hospital                                             63.2 (12/19)                                                    0.0001
  Transferred from a skilled nursing facility                                         40.3 (29/72)                                                    0.0002
  Comorbidities                                                                                                                                       
   Congestive heart failure                                                           24.3 (127/522)                                                  0.0227
   History of coronary disease                                                        26.1 (139/532)                                                  0.0006
   Immunosuppressive medication                                                       26.0 (19/73)                                                    0.3032
   Cancer                                                                             23.9 (11/46)                                                    0.5829
   Peripheral vascular disease                                                        32.2 (260/807)                                                  \<0.0001
   Chronic liver disease                                                              25.8 (8/31)                                                     0.5033
   Chronic lung disease                                                               24.1 (56/232)                                                   0.1993
   Previous stroke                                                                    23.9 (56/234)                                                   0.2025
   Chronic renal disease                                                              28.8 (128/445)                                                  \<0.0001
   History of amputation                                                              31.3 (191/611)                                                  \<0.0001
   Renal dialysis treatment                                                           41.5 (22/53)                                                    0.0005
  Type of skin and soft tissue infection                                                                                                              \<0.0001
   Cellulitis                                                                         16.9 (302/1,788)                                                
   Infected ulcer                                                                     32.8 (118/360)                                                  
   Surgical site                                                                      52.4 (43/82)                                                    
  Acute clinical presentation                                                                                                                         
   Systolic blood pressure \<100 mmHg                                                 24.6 (72/293)                                                   0.0892
   Temperature \<96°F or \>100.5°F                                                    27.0 (184/681)                                                  \<0.0001
   Pulse \<49 or \>125 bpm                                                            24.2 (31/128)                                                   0.3138
   Respiration \<10 or \>29 breaths per minute                                        25.6 (22/86)                                                    0.2776
   Altered mental status                                                              23.7 (41/173)                                                   0.3293
  Laboratory results                                                                                                                                  
   Albumin \<2.8 g/dL                                                                 36.7 (87/237)                                                   \<0.0001
   Blood urea nitrogen \>40 mg/dL                                                     23.6 (94/399)                                                   0.1341
   Creatinine \>3 mg/dL                                                               35.8 (63/176)                                                   \<0.0001
   Sodium \>145 mEq/dL                                                                25.0 (6/24)                                                     0.6133
   Total bilirubin \>0.8 mg/dL                                                        23.8 (49/206)                                                   0.2791
   pO~2~ \<55 or \>140 or O~2~ sat \<90%                                              21.6 (8/37)                                                     0.8398
   Prothrombin time international normalized ratio \>1.2 or prothrombin time \>14 s   37.8 (79/209)                                                   \<0.0001
   Bands on leukocyte differential \>13%                                              26.3 (21/80)                                                    0.2092
   White blood cell count \>11,000 per mm^3^                                          30.3 (314/1,037)                                                \<0.0001
  Glucose on admission (mg/dL)                                                                                                                        0.0603
   ≤70                                                                                12.0 (12/100)                                                   
   71--135                                                                            18.1 (60/331)                                                   
   136--240                                                                           22.0 (158/717)                                                  
   \>240                                                                              21.5 (233/1,082)                                                

\*Fisher exact test.

Multivariable LEA predictive model {#s10}
----------------------------------

Using stepwise regression analysis, we found 11 independent predictors of LEA ([Table 3](#T3){ref-type="table"}). The most highly significant (*P* \< 0.0001) were SSI, vasculopathy, previous LEA, and white blood cell count \>11,000 per mm^3^. The predictive model developed using these predictors had very good discrimination (c-statistic 0.76) and excellent calibration between predicted and observed LEA rates (Hosmer-Lemeshow test showing that they did not significantly differ across risk deciles; *P* = 0.63) ([Fig. 1](#F1){ref-type="fig"}). Patients in the highest risk decile had a predicted probability of LEA of 59.4% and an observed LEA rate of 58.7%, whereas those in the lowest decile had a predicted probability of LEA of 4% and an observed LEA rate of 5%. The predictive model yielded a good calibration when applied to the validation cohort (Hosmer-Lemeshow test; *P* = 0.33).

###### 

Multivariable model and risk score for LEA

  Risk factor                                                                    Coefficient   Odds ratio (95% CI)   *P*        Risk score weight[\*](#t3n1){ref-type="table-fn"}
  ------------------------------------------------------------------------------ ------------- --------------------- ---------- ---------------------------------------------------
  Chronic renal disease or creatinine \>3 mg/dL[†](#t3n2){ref-type="table-fn"}   0.1372        1.15 (0.89--1.49)     0.2998     1
  Male sex[†](#t3n2){ref-type="table-fn"}                                        0.1988        1.22 (0.97--1.54)     0.0963     1
  Temperature \<96°F or \>100.5°F                                                0.2830        1.33 (1.05--1.68)     0.0187     2
  Age ≥50 years                                                                  0.5477        1.73 (1.28--2.34)     0.0004     4
  Infected ulcer versus cellulitis                                               0.5168        1.68 (1.27--2.21)     0.0002     4
  History of amputation                                                          0.5020        1.65 (1.29--2.11)     \<0.0001   4
  Albumin \<2.8 g/dL                                                             0.6203        1.86 (1.35--2.56)     0.0001     5
  History of peripheral vascular disease                                         0.7485        2.11 (1.66--2.69)     \<0.0001   5
  White blood cell count ≥11 (1,000 per mm^3^)                                   0.9596        2.61 (2.07--3.30)     \<0.0001   7
  Surgical site vs. cellulitis                                                   1.3845        3.99 (2.44--6.55)     \<0.0001   10
  Transferred from other acute-care facility                                     1.6418        5.16 (1.78--15.02)    0.0026     12

\*We used the method described by Sullivan et al. ([@B11]) to calculate the risk score weight: Step 1: divide each regression coefficient by the smallest coefficient in the model (in our model, this is chronic renal disease or creatinine \>3 mg/dL). Step 2: round this quotient to the nearest whole number. For example, to calculate the score weight of male sex, we divided its coefficient of 0.1988 by 0.1371, resulting in a quotient of 1.44. Rounding this quotient to its nearest integer resulted in 1 for the score weight of this variable. We then calculated each subject's overall LEA risk score by summing the points of all variables present on admission.

†We retained these two variables for clinical plausibility despite the fact that they are not statistically significant at the 0.05 level in the model.

![Comparison of the predicted probability of LEA against the observed amputation rate for both derivation and validation cohorts, by decile. The diagonal line represents perfect correlation of predicted and observed LEA rates. Model Hosmer-Lemeshow goodness-of-fit test χ^2^ = 6.2, *P* = 0.63 vs. χ^2^ = 9.2, *P* = 0.33 for the derivation vs. the validation cohorts, indicating excellent fit of the model.](1695fig1){#F1}

Simplified risk score strata {#s11}
----------------------------

For each patient, we summed all the variables present on admission to create an LEA risk score. We then grouped the risk scores into five risk strata. The use of a five-level risk strata allows easy application of risk stratification for comparisons of outcomes. LEA rates in the derivation and validation cohorts increased significantly by risk score strata (*P* \< 0.0001 by the Cochran-Armitage trending test for both derivation and validation cohorts) ([Fig. 2](#F2){ref-type="fig"}). For the derivation cohort, the risk of LEA for patients aged \<50 years and without any of the other 10 factors in the risk score system was essentially zero. In contrast, for those whose score was ≥21, LEA risk was \~50%. The findings in the validation cohort were similar to those in the derivation cohort.

![Observed LEA rates by risk score strata for both derivation and validation cohorts (Cochran-Armitage trending test, *P* \< 0.0001).](1695fig2){#F2}

CONCLUSIONS {#s12}
===========

In this large cohort of patients hospitalized for a diabetic foot infection, more than one-fifth required an LEA. In reviewing numerous clinical and laboratory variables present at hospital admission in our derivation cohort, we identified 11 significant independent risk factors for LEA. By rounding the logistic regression coefficients into integers, we developed a simple LEA risk score system with five strata that we demonstrated was highly predictive of the risk for LEA. Using the patients in the validation cohort, we were then able to demonstrate that this risk score was indeed valid and well calibrated.

Most of the factors included in our risk score have been reported as risks for LEA in smaller, previously published studies ([@B7],[@B12],[@B13]). The presence of infection and peripheral vascular disease are the most powerful predictors. Most patients with diabetic foot ulcers do not have a fever or leukocytosis ([@B14]), which define a severe infection according to the Infectious Diseases Society of America and the International Working Group on the Diabetic Foot criteria. These severe diabetic foot infections are associated with a greater risk of LEA than those of mild or moderate severity. Previous studies ([@B15],[@B17]) also have identified renal insufficiency as being associated with an increased risk of amputations. Other studies have identified increasing age ([@B18]), male sex ([@B16]), and hypoalbuminemia ([@B19]) as risks for LEA. Likewise, a previous LEA is a strong risk factor predicting the need for another amputation ([@B12]). In none of these previous studies, however, did the authors attempt to construct a scoring system to predict amputation risk for both men and women.

In a previous study ([@B20]), we showed that patients with SSIs who were transferred from another acute-care facility had worse clinical and economic outcomes, perhaps because patients with infections of greater severity are more likely to be transferred to hospitals with more intensive resources or greater expertise. A recent meta-analysis ([@B21]) demonstrated a direct association between hyperglycemia (as measured by hemoglobin A~1c~) and LEA. Unfortunately, we did not have hemoglobin A~1c~ values on most of our patients, but we did note a nonsignificant trend toward higher amputation rates in those with increased blood glucose levels on admission. All of our patients had an infection; therefore, that variable was not among those included in our scoring system. It is noteworthy that the type of infection was associated with amputation risk, with SSIs at the highest risk, followed by infected ulcers, when compared with cellulitis. Our assumption is that these SSIs may be associated with failed lower-extremity bypass procedures. We found no other studies that investigated the risk of adverse outcomes in patients with an infected ulcer compared with cellulitis or SSIs. We did find other studies ([@B7],[@B14],[@B22],[@B23]) that reported that deep infections (especially those involving bone) and necrotizing infections more often resulted in amputations.

The simplified five risk strata that we devised correlated strongly with LEA rates. This may have important clinical implications on how to allocate resources. In particular, a patient with a low score may need fewer medical resources than a patient with a high LEA risk score. At the other extreme, to try to avoid the tragedy of amputation, health care providers should concentrate efforts on a patient with a risk score of \>21, who has a 50% chance of an LEA. Our finding that patients transferred from another acute-care hospital had the highest odds ratio for LEA highlights the need of risk adjustment to appropriately evaluate outcomes for hospitals treating the most severe patients. Because LEA rates are sometimes used to compare quality of care for patients with diabetic foot complications, our risk adjustment score could be used to ensure that centers treating higher-risk patients are not unfairly penalized. Furthermore, although this has not been tested, the score might be helpful to clinicians in deciding which patients with diabetic foot infections may need to be hospitalized. The LEA risk score system has the benefit of being simple to use; each of the risk factors is readily available, usually at the time of admission or soon afterward.

Our study is limited by the fact that our analysis was retrospective, and, although fairly inclusive, we could have missed potentially significant factors. For example, the individual reasons for amputation and whether amputation was elective or urgent were not captured in the database. One major risk factor that we did not capture that could have an effect on our risk score is a history of a previous lower-extremity revascularization procedure, which was a significant factor in other reports ([@B24],[@B25]). Selection bias is another potential limitation when using administrative data to identify patients with skin or soft-tissue infections. To minimize potential bias related to the use of ICD-9 coding, we limited our study to culture-confirmed infections.

In conclusion, we used a large clinical database to develop and validate a risk score that seems to accurately stratify LEA risk among patients hospitalized for a diabetic foot infection. This score may help clinicians identify patients at highest risk of LEA upon admission. Once patient identification is achieved, methods to reduce the risk can be investigated. We would like to see our risk score validated prospectively, including in patients treated on an outpatient basis.
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======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0331/-/DC1>.
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